• R Launois, M Toumi, J Reboul-Marty, and C Lançon.
• Faculté de Médecine Léonard de Vinci, Institut de Recherche et d'Evaluation Médicale et Economique (IREME), Bobigny.
• Encephale. 1998 Mar 1;24(2):83-99.

AbstractThe cost of schizophrenia has been a major point of interest abroad. In the United States, two authors evaluated the direct cost of the illness. According to Gunderson and Mosher (13), it reaches US $25,625 million. In the United Kingdom, the estimations are of 390 million pounds (7) and 1,178 million pounds (16). In Australia, a direct cost calculation based on incidence leads to US $24,621 million (1), which is 6 times as much as the cost of infarction. At last, the only French study (Rouillon et al., 1997) gives a result of FF 17,911 millions. The indirect cost estimations vary from 71% (29) to 83% (13) of the total cost. The difference between the 6 publications are suprizing (especially when they concern the same country) and are probably link to the difference of methodology. This point tempers largely the interest of these studies as a tool in order to hierarchise Public Health priorities. Moreover, the elaboration of structures equivalencies between the different countries is an ambitious enterprise and make difficult comparisons of the studies. Finally, the lack of transparency of some of them limits their credibility.

11 keywords...

hide…